经鼻点滴枸橼酸芬太尼注射液用于控制爆发性癌痛临床观察.docVIP

经鼻点滴枸橼酸芬太尼注射液用于控制爆发性癌痛临床观察【摘要】 目的 探讨经鼻点滴枸橼酸芬太尼注射液用于控制爆发性癌痛(BTCP)的有效性。方法 18例晚期癌症且合并BTCP住院患者，均口服吗啡缓释片控制基础性癌痛，口服吗啡即释剂控制BTCP。随机分为两组(n=9)：观察组在BTCP时改用枸橼酸芬太尼注射液1 ml(50 μg)滴鼻。对照组：继续用吗啡即释剂控制BTCP。结果 观察组与对照组镇痛起效时间分别为(1834±633)和（2511±426） min，观察组显著短于对照(P005)。观察组BTCP最大强度评分显著低于对照组(P005)，而患者满意度评分显著高于对照组(P001)。结论 枸橼酸芬太尼注射液滴鼻用于控制BTCP，给药方便，起效迅速，患者满意度高，有一定的临床应用价值。 【关键词】 枸橼酸芬太尼注射液；鼻腔点滴给药；爆发性癌痛 Clinical observation of intranasal fentanyl citrate for the treatment of breakthrough cancer pain ZHANG Jinzhi, DENG Ruoxi, XU Xianghui, et al Department of Anesthesiology, Shenzhen Hospital of Peking University, Shenzhen 518036, China 【Abstract】 Objective To investigate the effectiveness of intranasal fentanyl citrate for the treatment of breakthrough cancer pain(BTCP) Methods 18 hospitalized terminal cancer patients combined with BTCP were taken morphine sustained release tablets to control background pain while morphine immediate release tablets to treat BTCP They were randomized to two grounds(n=9), observation group (IF) patients used intranasal fentanyl citrate 1 ml (50 μg) when BTCP occurred and normal group (NM)patients continued to use morphine tablets Results The onset time of analgesia in IF group and NM group were (1834±633)min and (2511±426)min The IF group were obviously shorten than NM group(P005) The scores of BTCP maximum level were lower(P005) and degree of satisfaction were higher in IF group (P001)compared with NM group Conclusion Intranasal fentanyl citrate for the treatment of breakthrough cancer pain are convenient in administration and fast onset, patients get high degree of satisfaction and also have a certain clinical practice values. 【Key words】 Fentanyl citrate; Intranasal; Breakthrough cancer pain(BTCP) -------------------------------------------------------------------------------- 作者单位：518036 深圳,北京大学深圳医院麻醉科 爆发性癌痛(breakthrough cancer pain，BTCP)是一种突然发作的、可“突破”有效镇痛药物治疗效力的短暂剧烈疼痛。在晚期癌症患者中，其发生率约70%~80%。在积极控制基础性癌痛(background pain)的基础上有效缓解